Evidence-Based Diuretic Therapy for Improving Cardiovascular Prognosis in Systemic Hypertension - 06/08/11

Résumé |
Diuretics are among the most commonly prescribed cardiovascular (CV) medications. The strength of evidence supporting the effectiveness of diuretics in lowering blood pressure and for preventing major adverse CV events in patients with hypertension varies considerably among diuretic classes and even among agents within the same class. Unfortunately, common prescribing habits among American physicians, including specialists in CV diseases, are not in line with the existing evidence regarding diuretic therapy for improving CV prognosis. In conclusion, although hydrochlorothiazide is the standard diuretic used for hypertension, the outcomes data suggest that chlorthalidone, indapamide, and possibly even the aldosterone receptor blockers (spironolactone and eplerenone) may be superior agents.
Le texte complet de cet article est disponible en PDF.Plan
| Dr. Lavie is a speaker and consultant for GlaxoSmithKline, Research Triangle Park, North Carolina; Pfizer, Inc., New York, New York; and Abbott Laboratories, Abbott Park, Illinois. Dr. O'Keefe is a speaker and consultant for Pfizer, Inc., and a speaker for AstraZeneca, Wilmington, Delaware, and Forest Pharmaceuticals, Inc., New York, New York. |
Vol 107 - N° 8
P. 1178-1184 - avril 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
